Th is study aimed to determine whether inhaled prostaglandins are associated with improvement in pulmonary physiology or mortality in patients with ARDS and assess adverse eff ects .
In terms of mortality and survivor morbidity, ARDS exacts a signifi cant toll on patients and the health-care system. 1 Shunt physiology drives hypoxemia; pulmonary hypertension is common and may have adverse prognostic signifi cance. [2] [3] [4] [5] Th e use of inhaled pulmonary vasodilators, which could improve oxygenation by preferentially improving perfusion to well-ventilated lung regions and reduce pulmonary pressures, therefore, has physiologic rationale. Inhaled nitric oxide (iNO) continues to be used for a signifi cant minority of patients with ARDS. 6, 7 While shown to improve oxygenation, meta-analyses of randomized trials demonstrate no mortality benefi t with iNO, and an association with harm. 8, 9 It is unknown whether other inhaled pulmonary vasodilators are associated with similar physiologic or clinical outcomes.
The inhaled prostaglandins epoprostenol (prostaglandin I 2 [PGI 2 ]; Flolan) and alprostadil (prostaglandin E 1 [PGE 1 ]) promote pulmonary vasodilation via a cyclic adenosine monophosphate-mediated decrease in intracellular calcium. 10 Th ey also have antiinfl ammatory and antiplatelet aggregation properties, providing further potential mechanistic benefi t in ARDS. [10] [11] [12] [13] [14] [15] One observational study demonstrated the use of inhaled epoprostenol in 22% of patients with severe ARDS treated with extracorporeal support. 16 A systematic review that included only one randomized controlled trial (RCT) of 14 pediatric patients concluded that enough evidence did not exist to support or refute the use of inhaled epoprostenol in ARDS. 17 However, other clinical studies have been completed since this review was published. As such, it is unknown whether the use of inhaled prostaglandins in ARDS provides any benefi t.
Th erefore, the objectives of this study were to perform a systematic review of the literature, including RCTs and observational studies, to determine whether the inhaled prostaglandins epoprostenol and alprostadil are associated with an improvement in pulmonary physiology (eg, oxygenation, pulmonary artery pressures) or mortality in postneonatal children and adults with ARDS. An assessment of the adverse eff ects associated with this therapy was also an aim of interest. Based on the existing data regarding iNO, the primary hypothesis was that the use of inhaled prostaglandins would be associated with an improvement in oxygenation and pulmonary artery pressures, but would not confer any mortality benefi t.
Materials and Methods
This systematic review was designed, conducted, and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) ( e-Appendix 1 ) and Meta-analysis of Observational Studies in Epidemiology (MOOSE) ( e-Appendix 2 ) guidelines. 18, 19 It was registered with PROSPERO (registration number CRD42014013180). Ethical approval from the Human Research Protection Offi ce at the principal investigator's institution was not required.
Search and Identifi cation of Studies
A written protocol ( e-Appendix 3 ) that was fi nalized prior to beginning the search was followed. Th e timeline was from 1976 (discovery of PGI 2 ) through 2014, and searched PubMed, EMBASE, Cumulative Index of Nursing and Allied Health Literature (CINAHL), the Cochrane Central Register of Controlled Trials (CENTRAL), and the Cochrane Database of Systematic Reviews. Searches were completed in May 2014. A trained medical librarian (S. F.) experienced in systematic reviews assisted in designing the search strategy and in conducting the electronic search. Two authors (B. M. F. and N. M. M.) also manually screened reference lists of articles selected for inclusion to identify additional studies. To identify potential unpublished data, B. M. F. also (1) 
Inclusion Criteria
RCTs were included, as well as nonrandomized studies (prospective interventional studies, prospective and retrospective cohort analyses, case series). Th e inclusion of nonrandomized studies was decided a priori for the following reasons: (1) high likelihood the question of interest could not be investigated strictly with RCTs secondary to lack of existing randomized trials; (2) to provide an explicit evaluation of strengths and weaknesses of the current literature; (3) to assess evidence of eff ects (benefi t and harm); and (4) to provide evidence for the undertaking of randomized trials. 20 Th e intervention was inhaled epoprostenol or inhaled alprostadil; the comparison was placebo or no intervention/usual care, as well as iNO, provided that all crossover studies reported data transparently. Studies of hypoxemic patients that did not explicitly state the population was ARDS were excluded. Studies that did not report preintervention and postintervention data, such as the eff ect on oxygenation, were excluded. Papers that were reviews, correspondences, editorials, and nonhuman studies were also excluded. Th e reference list of all review articles was screened to identify additional studies for inclusion.
Study Selection and Data Abstraction
Two reviewers (B. M. F. and N. M. M.) independently screened titles and abstracts of identifi ed studies for eligibility. Aft er this relevance screen, full text articles were assessed for eligibility, and the two reviewers compared their exclusion logs to determine whether there was disagreement. All studies deemed potentially relevant aft er the screen were obtained and the full manuscripts were reviewed (B. M. F., N. M. M., and L. S.). In cases of disagreement, a consensus was reached among the three reviewers. 
Assessment of Study Quality
Th e quality of clinical trials selected for inclusion was assessed by using the Cochrane Collaboration Tool for assessing the risk of bias in clinical trials. 21 High quality was defi ned as a grade of "A" in at least three of the four methodology domains. For studies of observational design, quality was assessed with the Newcastle-Ottawa Scale, assigning a maximum of nine points. 22, 23 Five or fewer points indicated a high risk of bias.
Assessment of Publication Bias
A graphic display (funnel plot) of the size of the treatment eff ect against the precision of the trial was used to evaluate for potential publication bias. 24 
Data Analysis
During the conduct of the systematic review, a scoping review of the literature revealed a lack of controls from which to compare mortality or adverse events. 25 Th erefore, the decision was made to assess physiologic end points as the primary outcomes, including oxygenation parameters (Pa o 2 to F io 2 ratio and Pa o 2 ), and mean pulmonary artery pressure (mPAP). Secondary outcomes included mortality and adverse eff ects.
Meta-analysis:
Review Manager (RevMan, Version 5.1; Th e Nordic Cochrane Centre, Th e Cochrane Collaboration) was used to conduct the meta-analysis. A generic inverse variance, random eff ects model was used. Continuous data are reported as mean diff erence (measure of absolute change). Overall effect estimates were generated using a Z test and presented as mean diff erences (measures of absolute change). A P value of Յ .05 was considered statistically signifi cant. Th e decision to combine the data on epoprostenol and alprostadil was made a priori. Th e decision to not combine evidence from randomized trials and nonrandomized studies was also made a priori, as per expert recommendation. 20 Stratifi ed subgroup analyses were performed, as were sensitivity analyses, which excluded the study with the largest mean diff erence in Pa o 2 to F io 2 ratio and the largest number of patients. 26, 27 Heterogeneity between studies was assessed using the I 2 statistic, with suggested thresholds for low (25%-49%), moderate (50%-74%), and high ( Ն 75%) values. 28, 29 During the systematic review, it was evident that the secondary outcomes (mortality and adverse eff ects) could not be assessed quantitatively. A post hoc decision was, therefore, made to report overall mortality and reported adverse eff ects in a descriptive, qualitative fashion. A post hoc decision to use a x 2 test to compare differences in the rate of hypotension between the observational cohort studies (longer exposure to inhaled prostaglandins) and the prospective studies (very brief exposure to inhaled prostaglandins) was also made.
Meta-Regression:
The I 2 statistic indicated significant heterogeneity among the entire collection of data. Subgroup analysis and meta-regression were performed to explain some of the heterogeneous effect sizes between studies. Possible sources of heterogeneity tested included baseline oxygenation, pulmonary vasodilator dosing, source of ARDS (pulmonary vs nonpulmonary), and study year. A linear meta-regression model weighted to refl ect the variance of the individual studies was used to model the data. OpenMeta [Analyst] (Center for EvidenceBased Medicine, Brown School of Public Health) was used for regression with continuous covariates. 30 
Results

Search and Selection
Th e comprehensive search yielded a total of 380 potentially relevant publications. Details regarding the search, study selection, and reason for exclusion are shown in Figure 1 .
Inclusion
Aft er the relevance search, a complete manuscript review was performed on the remaining 47 articles. Twenty-fi ve studies were included in the fi nal analysis.
Study Characteristics and Outcomes Reporting
Th e characteristics of the included studies are shown in Tables 1 and 2 . 26, 27, Two studies were RCTs, six were prospective, nonrandomized interventional studies, 10 were observational studies, and seven were case series. Th e total number of patients across studies was 606 (n 5 497 epoprostenol, n 5 109 alprostadil, median 11 patients per study).
Th e RCTs were rated as high quality by the Cochrane Collaboration Tool for assessing the risk of bias in clinical trials. On the nine-point Newcastle-Ottawa Scale, the median risk of bias score was 5, indicating a high risk of bias. Th e main risk of bias was selection bias (eg, lack of a nonexposed cohort) and information bias (eg, lack of description in outcome assessment). As assessed by the Cochrane Collaboration Tool for assessing risk of bias in clinical trials. Four domains were assessed: random sequence generation, concealment of allocation, blinding, and selective outcome reporting. High quality was defi ned as a grade of "A" in at least three-fourths of the methodology domains. To explain, for trials where blinding is not feasible at the point of intervention, a grade of "A" would be assigned if the investigator collecting the primary outcome was blinded to the treatment allocation.
c Some outcomes were not explicitly stated or defi ned in the manuscript as primary or secondary outcomes, but reported as such in the table.
The primary outcome was physiologic in 24 of 25 studies (ie, oxygenation, pulmonary artery pressures) and clinical (ie, lengths of stay, mortality) in four of 25 studies. Th ere was a wide range of delivered doses ( e- Table 1 ).
Eff ect of Inhaled Prostaglandins on Physiologic Outcomes
Th e results of the two RCTs are reported separately and qualitatively. 20, 34, 43 One crossover randomized trial, using nebulized normal saline placebo, assessed the eff ect of epoprostenol on oxygenation index [(F io 2 
Meta-analysis:
Aggregate meta-analysis of the remaining datasets (excluding the two RCTs) is presented in ( Fig 3 ) revealed possible reporting bias with asymmetric skew to the left . 54 Th ere was signifi cant statistical heterogeneity for each outcome.
To examine sources of heterogeneity in the aggregate meta-analysis and sources of variation in individual study results, additional stratifi ed meta-analyses were performed. For these subgroups, analyses were restricted to (1) type of inhaled pulmonary vasodilator (epoprostenol or alprostadil), (2) publication year, (3) study type, (4) risk of bias, and (5) exclusion of case series. Metaanalysis of the data from the prospective, nonrandomized interventional studies was conducted separately from the observational studies and case series, in accordance with guideline recommendations of meta-analyses of nonrandomized studies. 20 Th is was done to decrease heterogeneity across study types, as the interventional As assessed by the Newcastle-Ottawa Quality Assessment Scale. c Some outcomes were not explicitly stated or defi ned in the manuscript as primary or secondary outcomes, but reported as such in the table. Meta-regression: Linear meta-regression was used to assess the impact of continuous covariates on treatment eff ect. Year of publication ( P 5 .862), baseline Pa o 2 to F io 2 ratio ( P 5 .106), and proportion of nonpulmonary ARDS ( P 5 .816) were not associated with the treatment eff ect. A dose-response relationship was tested among studies that reported data separately for cohorts with a defi ned dose, and higher doses of inhaled prostaglandins increased Pa o 2 to F io 2 ratio linearly ( Fig 4 ) .
Adverse eff ects
Adverse events were variably reported overall. Twenty studies mentioned adverse events, or a lack of adverse eff ects (eg, "no eff ect on blood pressure"), somewhere in the manuscript ( e- Table 2 ). Eleven studies reported no eff ect on systemic hemodynamics, while fi ve studies reported hypotension, ranging from an incidence of 12.5% to 33.3%. Th ere was a statistically signifi cant diff erence in the rate of hypotension between the prospective studies vs the observational studies, 0.69% (1 of 144) vs 27 of 155 (17.4%) ( P , .001). Th ree studies reported thrombocytopenia, anemia, or transfusion requirement.
Mortality
Mortality was reported in 17 of 25 studies ( e- Table 3 ). Due to lack of controls, an investigation into an association of inhaled prostaglandin with mortality could not be ascertained. Th e overall reported mortality in patients with ARDS receiving inhaled prostaglandins was 295 of 522 (56.5%).
Discussion
In patients with ARDS, the traditional inhaled pulmonary vasodilator of choice has been iNO, with little data on inhaled prostaglandins. Th is systematic review and meta-analysis was, therefore, undertaken to assess outcomes associated with inhaled prostaglandins. Th e fi rst fi nding is that inhaled prostaglandins appear to be used with some frequency in ARDS. Th is is demonstrated by the 25 publications included in the analysis, as well as the discovery of several other studies not meeting the inclusion criteria. [55] [56] [57] [58] [59] [60] [61] [62] Th e data would also suggest that use is increasing in frequency, as approximately 75% of the patients were from studies published in the last 3 years. This is an interesting phenomenon when put into context of other fi ndings in this analysis: (1) a lack of clinical outcome data demonstrating benefi t, (2) overall low quality for the majority of data, and (3) signifi cant heterogeneity in the data that does exist.
Only one study, to our knowledge, reported a clinical outcome as a primary analysis of interest. Th e two RCTs that exist had very brief exposure to study drug and did not study patient-centered outcomes. Furthermore, one RCT included only children, a potentially unique population with respect to ARDS incidence, outcome, and response to therapy. 63, 64 Th e majority of observational studies were low quality. Th is suggests a lack of transparency and signifi cant potential for bias in the published literature. Heterogeneity was demonstrated not only statistically, but also in a clinical overview of the reported data with respect to dosing, duration of exposure, and timing of therapy.
Aggregate meta-analysis and stratifi ed subgroup analyses show improved oxygenation in ARDS. Similar results have been demonstrated with iNO, yet there is a lack of correlation between changes in oxygenation and outcome benefi t in ARDS. 8, 9, 65, 66 Furthermore, the majority of studies measured oxygenation changes in a before-aft er fashion, suggesting that the oxygenation benefi t should be interpreted with caution. Without a placebo, it is impossible to assess whether oxygenation benefi t was secondary to the use of inhaled prostaglandins. Consistency across data suggests this, but in a dose-fi nding study of iNO, 24% of the placebo group had an increase in Pa o 2 of Ն 20%. 67 Similar placebo eff ects were seen in one RCT included in this review. 43 Furthermore, some of the cohort studies specifi cally excluded patients whose oxygenation did not respond to therapy, and although averaged measures of oxygenation were found to improve for the group overall, multiple studies report that a signifi cant percentage of patients were nonresponders. [34] [35] [36] 39, 44 So, it is possible that inhaled prostaglandins confer no oxygenation benefi t, and these results refl ect improved oxygenation secondary to a change in F io 2 or other concomitant therapies that were not reported (eg, prone positioning, positive end-expiratory pressure setting).
Descriptive analysis of cohort studies suggests that patients dosed with inhaled prostaglandins experience adverse events that are serious and fairly common. Specifi cally, hypotension was reported in 17.4% of patients in the cohort studies. Th is is in contrast to the prospective interventional studies, which reported adverse events with less frequency. Th is may be secondary to the diff erence in drug exposure between the two study types, as the treatment duration in the cohort studies was signifi cantly longer. Th ere is biologic plausibility, as a prostaglandin metabolite, of 6-keto PGF1 a , has been measured in the systemic circulation and demonstrates that the eff ect of inhaled prostaglandins is not isolated to the lung. 50 Th e lack of a control group in these studies also makes it diffi cult to conclude that the reported adverse events were related to inhaled prostaglandin therapy. Little data were provided on other ARDS treatments, such as adherence to lung-protective ventilation, and selective reporting of adverse events was common. However, the reported rate of hypotension in the cohort studies suggests that inhaled prostaglandins may be associated with possible harm and raises concern about prolonged exposure in the routine setting of ARDS treatment.
iNO does not reduce mortality in patients with ARDS. 9 Inasmuch as inhaled prostaglandins may have a similar eff ect on hypoxemia and pulmonary hypertension as iNO, if the only eff ect of inhaled prostaglandins is on this physiology, then it is unlikely that they will improve long-term clinical outcome either. However, there is also biologic plausibility that a potential eff ect of inhaled prostaglandins could be derived from their antiplatelet and antiinfl ammatory properties. [10] [11] [12] [13] [14] [15] Th is may be more impactful as far as meaningful clinical outcome is concerned, but needs to be studied further. Reported ARDS mortality rate was 56.5% in patients treated with inhaled prostaglandins. While no inference on causation can be drawn, with this mortality rate exceeding that in reported ARDS literature, it is unclear that any benefi t is derived.
Th ere are important limitations in this systematic review. Due to a lack of RCTs, unpublished and nonrandomized studies were included in the analysis. 68, 69 Th is decision has several implications. By including nonrandomized trials, biases in the primary data are likely to be greater. 20 An attempt to control for this was done by systematically grading each study for bias and reporting these results transparently. Nonrandomized trials oft en lead to increased heterogeneity, which was demonstrated in a clinical overview of the data reported, as well as statistically. Stratifi ed subgroup meta-analyses were conducted in an attempt to control for this, and these gave similar results as the aggregate data. Metaregression analysis was also performed. Confounding is also an issue with nonrandomized studies. It is possible that clinicians dosed patients with ARDS with inhaled prostaglandins based on a higher likelihood of clinical response or survival (ie, confounding by indication). A mortality rate of 56.5% speaks against this. On the other hand, it is also possible that clinicians chose to dose patients with the most severe ARDS with inhaled prostaglandins, and the high mortality rate is a refl ection of ARDS severity and a lower chance of survival. It is also possible that the search did not uncover all of the published literature in this domain, as nonrandomized studies are indexed poorly and have a lack of study registries. Th e search was exhaustive, rigorous, and reproducible, giving confi dence that the largest amount of data on this topic to date was uncovered. Finally, while ARDS was an explicit inclusion criterion for this systematic review, not every individual study stated how ARDS was defi ned. An assumption would be that consensus defi nitional criteria for ARDS were used, but without an explicit statement to this fact in each publication, we are unsure. 70, 71 It is recognized that these limitations make drawing conclusions on the use of inhaled prostaglandins for ARDS diffi cult. It, therefore, must be emphasized that due to the paucity of quality data, this analysis cannot discern whether there is truly any benefi t or harm. However, this analysis provides an explicit evaluation of the strengths and weaknesses of the current literature to date, and by demonstrating a signal in the data for both benefi t (ie, physiologic eff ects) and harm (ie, rate of hypotension), evidence for the need for randomized trials in this area has been provided.
Conclusions
Th e data regarding the use of inhaled prostaglandins for ARDS are limited both in terms of methodologic quality and demonstration of clinical benefi t. Meta-analysis demonstrates that inhaled prostaglandins improve oxygenation and decrease pulmonary artery pressures and may be associated with adverse events. Th e use of inhaled prostaglandins in ARDS is in need of further study.
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